Business Context and Reporting Period
Company: Delcath Systems, Inc.
Filing Type: Form 10-QSB (Quarterly Report)
Period Ended: September 30, 2000
Business Stage: Development stage company founded in 1988.
Core Activity: Developing a proprietary drug delivery system (Delcath system) for isolated perfusion of the liver to treat liver cancer and malignant melanoma. The company has received FDA approval to proceed with Phase III clinical trials using doxorubicin.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 2000 | Cumulative from Inception |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Costs & Expenses | $156,146 | $560,953 | $12,277,738 |
| Net Loss | $(154,527) | $(546,298) | $(11,858,260) |
| Cash & Equivalents (End of Period) | $453,344 | ||
| Short-Term Borrowings | $230,000 | ||
| Deferred IPO Costs | $516,545 |
Liquidity: Cash decreased by $107,734 during the nine-month period. Net cash used in operating activities was $323,014 for the nine months ended September 30, 2000.
Material Changes vs. Prior Period
- Operating Loss: Net loss for the nine months ended September 30, 2000, was $546,298, compared to $398,607 for the same period in 1999. This represents an increase in losses of approximately 37%.
- Expense Drivers: Total costs and expenses increased from $415,371 (9 months 1999) to $560,953 (9 months 2000). Legal, consulting, and accounting fees rose significantly from $511,496 (cumulative 1999) to $224,270 (9 months 2000 alone), reflecting preparation for the IPO.
- Debt: The company incurred $230,000 in short-term borrowings in August and September 2000, bearing 22% annual interest, which was not present in the prior comparable period.
Guidance, Outlook, and Risks
- Initial Public Offering (IPO): Completed on October 19, 2000, raising $7.2 million before offering costs. Net proceeds are estimated at approximately $5.3 million after expenses and preferred stock dividend payments.
- Future Operations: Management anticipates significant additional operating losses over the next three years due to Phase III clinical trials, regulatory activities, and the establishment of a sales organization.
- Cash Runway: Based on IPO proceeds and current cash, the company expects to fund operations through the end of 2001.
- Key Risks:
- Uncertainty regarding the successful completion of Phase III clinical trials and FDA approval.
- Dependence on additional financing if IPO proceeds are insufficient.
- High interest rate (22%) on short-term bridge loans due in May 2001.
Investor Verification Checklist
- Phase III Trial Status: Verify the commencement date and recruitment progress of the Phase III doxorubicin trials anticipated for Q1 2001.
- Debt Repayment: Confirm the company's ability to repay the $230,000 bridge loan plus accrued interest (approx. $267,400 total) due in May 2001.
- Capital Sufficiency: Monitor cash burn rates to ensure the $5.3 million net IPO proceeds are sufficient to reach profitability or the next funding milestone by end of 2001.
- Related Party Transactions: Review the terms of the $90,000 in promissory notes issued to the CEO and the Chairman's mother.